Progranulin

Progranulin Overview

English NameProgranulinApproved Drugs0
Drugs in Clinical Trials7Target SynonymGRN
Highest Development StagePhase 2 Clinical
English NameProgranulin
Target SynonymGRN
Approved Drugs0
Drugs in Clinical Trials7
Highest Development StagePhase 2 Clinical

Progranulin Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
PGN-H52H3
Human
HEK293
Human Progranulin Protein, His Tag, low endotoxin (MALS & SPR verified)
Total: 1
  • 1

Progranulin Background

Progranulin, a secreted glycoprotein, is encoded in humans by the single GRN gene. Progranulin consists of seven and a half, tandemly repeated, non-identical copies of the 12 cysteine granulin motif. Many cellular processes and diseases are associated with this unique pleiotropic factor that include, but are not limited to, embryogenesis, tumorigenesis, inflammation, wound repair, neurodegeneration and lysosome function. Haploinsufficiency caused by autosomal dominant mutations within the GRN gene leads to frontotemporal lobar degeneration, a progressive neuronal atrophy that presents in patients as frontotemporal dementia.

Progranulin Synonyms

CLN11, GEP, GP88, PCDGF, PEPI, PGRN

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
GRN Gene Therapy(Eli Lilly And Company)PR-006Phase 2 ClinicalEli Lilly And CompanyFrontotemporal Dementia
Details
TAK-594DNL-593; PTV:PGRN; TAK-594Phase 2 ClinicalDenali Therapeutics IncFrontotemporal Dementia
Details
AVB-101AVB-101Phase 2 ClinicalAviadoBio LtdFrontotemporal Dementia
Details
AL-101GSK-4527226; AL-101Phase 2 ClinicalAlector IncNerve Degeneration; Alzheimer Disease; Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis
Details
PBFT-02PBFT-02Phase 2 ClinicalUniversity Of PennsylvaniaFrontotemporal Dementia
Details
AG-01(A&G Pharm)AG-01(A&G Pharm)Phase 1 ClinicalA&G PharmaceuticalTriple Negative Breast Neoplasms; Mesothelioma; Carcinoma, Non-Small-Cell Lung
Details
VGN-R13VGN-R13
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland